Molecular and Clinicopathologic Characterization of HER2-overexpressed Squamous Cell Carcinoma of the Cervix
- 31 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 44 (4) , 323-330
Abstract
HER2 amplification in cervical cancer has been associated with worse clinical prognosis and a potential favorable response to HER2 inhibitors. Immunohistochemistry for the HER2 receptor is a universally accepted surrogate test for HER2 amplification, but no standardized scoring system currently exists for cervical carcinomas. In this study, we investigated HER2 overexpression in cervical squamous cell carcinoma and correlated it with HER2 amplification using fluorescence in situ hybridization (FISH) and molecular methods. Seventy-two cases of human papillomavirus-associated cervical cancer were retrospectively reviewed, and at least 2 representative tumor sections were stained for HER2. HER2 scoring was performed using the 2018 American Society of Clinical Oncology/College of American Pathologist breast cancer criteria, and cases with equivocal (2+) to positive (3+) expression were analyzed for HER2 amplification using FISH and next-generation sequencing. The average patient age was 50 yrs (range: 27–85 yr), with most patients being African American (73.6%) and diagnosed at FIGO stage I (65.3%). Nineteen (26.4%) had equivocal HER2 expression and 4 (5.5%) showed positive expression. Three of the 4 cases with positive expression had enough tumors for FISH, and all 3 were amplified. Three cases with equivocal expression showed HER2 polysomy on FISH, and none showed HER2 amplification. Late clinical stage, high tumor grade, and regional lymph node metastasis were significantly correlated with HER2 overexpression and HER2 amplification. Next-generation sequencing of the 3 HER2-amplified tumors showed amplification of various genes, including CD274, JAK2, BIRC3, and ERBB2, and a PIK3CA missense mutation. In summary, HER2 immunohistochemistry is a reliable predictive marker of HER2 amplification in cervical cancer.Keywords
This publication has 43 references indexed in Scilit:
- Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA‐mutant cervical carcinoma via the PI3K/AKT pathwayJournal of Medical Virology, 2023
- Recurrent or primary metastatic cervical cancer: current and future treatmentsESMO Open, 2022
- An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and ClassificationThe Journal of Pathology: Clinical Research, 2020
- Role and significance of HER-2/neu as a biomarker in the premalignant and malignant lesions of uterine cervixAnnals of Diagnostic Pathology, 2020
- Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survivalGenes, Chromosomes and Cancer, 2016
- HER2 aberrations in cancer: Implications for therapyCancer Treatment Reviews, 2014
- Genetic alterations in cervical carcinomas: Frequent low‐level amplifications of oncogenes are associated with human papillomavirus infectionInternational Journal of Cancer, 2002
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Prognostic significance of c -erb B-2 protein expression in carcinoma of the cervix treated with radiotherapyJournal of Cancer Research and Clinical Oncology, 1999
- c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervixCancer, 1994